Loading
Zenas BioPharma, Inc. Stock: price and insider trades · United States
US·Mcap US$1.7B
No insider purchase over the last 90 days. The latest was filed 29 Apr 2026.
Zenas BioPharma, Inc.: what insiders have been doing
Zenas BioPharma, Inc. is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 12 filings, from 5 insiders.
Not one open-market sale was filed. On the buying side, 4 insiders reported 11 purchases totalling €7.9M. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Biggest ticket of the year: €2.6M, bought by Fairmount Funds Management LLC and made public on 1 April 2026. On the buying side, the filings list 3 senior executives and 1 chief executive among the declarants.
In the case of 9 purchases, another manager of the company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last purchase on record was published on 29 April 2026, which is 172 days ago. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4.
With 12 filings in twelve months, the company is quieter than the median of 22 filings across the 5,458 companies we follow on the same exchange. Over the whole record (from 2024), the tally stands at 21 purchases and no sales.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
32
Thresholds
n/a
Buy Volume
€18M
21 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleLEON O. MOULDER Jr.10 buys
Hongbo Lu3 buys
Fairmount Funds Management LLC2 buys
Jason Raleigh Nunn1 buy
Patricia L. Allen1 buy
Patrick G. Enright1 buy
+1 other insider
Since the insiders bought
- +28.6%Entry US$19.32 · Close 16 Oct 2026 US$24.84
- +11.6%Entry US$22.26 · Close 16 Oct 2026 US$24.84
- +15.8%Entry US$21.46 · Close 16 Oct 2026 US$24.84
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Zenas BioPharma, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$47.88.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$25.40
Analyst consensus
8 analystsStrong buy
US$32.00Target US$47.88(+88%)US$59.00
Income statement
RevenueUS$10M
EBITDA-US$370.4M-3704% margin
Net income-US$377.7M-3777.4% margin
Valuation
PER (forward)-5.5x
P/Book6.5x
Beta-0.88
Balance sheet & cash
Market capUS$1.7B
Total debtUS$1.3M
Free Cash Flow-US$207.4M
Debt / Equity121%
Profitability & ownership
ROE-199.0%
ROA-34.4%
% insiders19.8%
% institutions101.5%
Last declaration on 19 August 2026
Declarations32 total
1,000,000 shares@ US$31.911.75% mcap100.0% of flowCommonSEC144:0001968582-26-000858
25,000 shares@ US$18.020.023% mcap8.2% of flowCommon StockSEC:0001104659-26-051889:0
Canonical exit: 27 Jul 2026 (T+90)
35,000 shares@ US$17.620.031% mcap11.2% of flowCommon StockSEC:0001104659-26-051889:1
Canonical exit: 28 Jul 2026 (T+90)
150,000 shares@ US$20.0033.5% of flowCommon StockSEC:0001104659-26-038546:0
Canonical exit: 29 Jun 2026 (T+90)
20,000 shares@ US$18.236.8% of flowCommon StockSEC:0001104659-26-038031:0
Canonical exit: 28 Jun 2026 (T+90)
34,000 shares@ US$19.3112.1% of flowCommon StockSEC:0001104659-26-038031:1
Canonical exit: 29 Jun 2026 (T+90)
5,000 shares@ US$23.77100.0% of flowCommon StockSEC:0001104659-26-015342:0
Canonical exit: 13 May 2026 (T+90)
57,000 shares@ US$17.9618.4% of flowCommon StockSEC:0001104659-26-009756:0
Canonical exit: 3 May 2026 (T+90)
50,000 shares@ US$16.3814.9% of flowCommon StockSEC:0001104659-26-002589:0
Canonical exit: 7 Apr 2026 (T+90)
63,158 shares@ US$19.00100.0% of flowCommon StockSEC:0001193125-25-239158:0
Canonical exit: 7 Jan 2026 (T+90)
▲
Same trade as the filing by Jason Raleigh Nunn, counted once · View ↗
63,158 shares@ US$19.00100.0% of flowCommon StockSEC:0001193125-25-239153:0
Canonical exit: 7 Jan 2026 (T+90)
105,265 shares@ US$19.00100.0% of flowCommon StockSEC:0001193125-25-238326:0
Canonical exit: 7 Jan 2026 (T+90)
316,219 shares@ US$19.0066.5% of flowCommon StockSEC:0001104659-25-098362:0
Canonical exit: 5 Jan 2026 (T+90)
36,928 shares@ US$20.8514.0% of flowCommon StockSEC:0001104659-25-098413:0
Canonical exit: 5 Jan 2026 (T+90)
25,000 shares@ US$6.673.4% of flowCommon StockSEC:0001104659-25-015145:0
Canonical exit: 19 May 2025 (T+90)
25,000 shares@ US$10.765.4% of flowCommon StockSEC:0001104659-24-125677:0
Canonical exit: 3 Mar 2025 (T+90)
7,500 shares@ US$15.002.3% of flowCommon StockSEC:0001104659-24-121081:0
Canonical exit: 16 Feb 2025 (T+90)
10,000 shares@ US$17.913.4% of flowCommon StockSEC:0001104659-24-101773:0
Canonical exit: 17 Dec 2024 (T+90)
2,879,006 sharesCommon StockSEC:0001415889-24-023609:0
180,635 sharesCommon StockSEC:0001104659-24-101030:0
164,523 sharesCommon StockSEC:0001104659-24-100765:0
25 of 32 declarations
About Zenas BioPharma, Inc.
Zenas BioPharma, Inc. is a biopharmaceutical company focused on developing innovative treatments for autoimmune diseases and immune-related disorders. It is listed on the XNAS market.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
